Biolytx Pharmaceuticals
Biolytx is an emerging drug development company confronting the crisis in antibiotic drug resistance through the advancement of a suite of antimicrobial peptide drug candidates for the treatment of serious pathogens with no current therapeutic options. The company focuses on developing peptides to kill antibiotic-resistant bacteria and has a portfolio based on the naturally occurring human CAP37 protein. Their technology aims to address the crisis in antibiotic development and declining approvals by creating novel antimicrobial peptides with a dual mechanism of action.
Industries
Nr. of Employees
small (1-50)
Biolytx Pharmaceuticals
Oklahoma City, Oklahoma, United States, North America
Products
BP001
Preclinical antibiotic and wound-healing peptide candidate intended for treatment of infected ocular wounds; IND filing anticipated by company in early 2018.
BP002
Preclinical peptide therapeutic candidate targeted for treatment of cystic fibrosis and hospital-acquired pneumonia; ongoing studies to enable IND filing.
BP001
Preclinical antibiotic and wound-healing peptide candidate intended for treatment of infected ocular wounds; IND filing anticipated by company in early 2018.
BP002
Preclinical peptide therapeutic candidate targeted for treatment of cystic fibrosis and hospital-acquired pneumonia; ongoing studies to enable IND filing.
Expertise Areas
- Antimicrobial peptide therapeutics
- Preclinical drug development and IND strategy
- Peptide structure–function mapping and crystallography
- Ophthalmic infectious disease therapeutics
Key Technologies
- Antimicrobial peptides (CAP37-derived)
- Peptide synthesis and overlap mapping
- Protein sequencing and cloning
- X-ray crystallography (protein structure determination)
News & Updates
April 26, 2016 – Excerpt from NewsOk: “Through an association with William Hagstrom of Alpha Bio Partners, Branch became acquainted with OU professor Anne Pereira, Ph.D. Pereira had co-founded Biolytx Pharmaceuticals with Hagstrom based on her groundbreaking work in developing peptides that kill antibiotic resistant bacteria.”
December 16, 2015 – Excerpt from OCRID: University of Oklahoma Health Sciences Center Professor Heloise Anne Pereira has been named a 2016 National Academy of Inventors Fellow, a high professional distinction awarded to academic inventors who have demonstrated a prolific spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development, and the welfare of society.
November 7, 2015 – Excerpt from NewsOK: A $500,000 investment from the i2E Inc.-managed Oklahoma Seed Capital Fund recently led a $1.1 million financing round in Oklahoma City-based Biolytx Pharmaceuticals Corp. Biolytx is developing a drug designed to promote wound healing and kill antibiotic resistant bacteria. This latest financing also included $200,000 from i2E-managed SeedStep Angels group, $250,000 from an Oklahoma venture capital fund and $150,000 in investment by Biolytx management.
March 25, 2015 – Excerpt from: Oklahoma JustGoodNews.Biz OKLAHOMA CITY — In 2004, i2E launched a “Meet the Scientist” speaker series in which Oklahoma researchers presented their findings to a local audience that was eager to hear about the potential of scientific discoveries. PHOTO: Dr. Anne Pereira, Dean of OU Health Sciences Center Graduate College…
December 8, 2014 – Excerpt from i2e: Just a few years ago, we lived in a world that wasn’t connected by wireless networks and instantaneous communication. So you might have felt a bit isolated if you were raised in, say, Australia. That was definitely the perception of Anne Pereira in the early 1980s as she…
University of Oklahoma Health Sciences Center Professor Heloise Anne Pereira has been named a 2016 National Academy of Inventors Fellow, a high professional distinction awarded to academic inventors who have demonstrated a prolific spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development, and the welfare of society.
April 26, 2016 – Excerpt from NewsOk: “Through an association with William Hagstrom of Alpha Bio Partners, Branch became acquainted with OU professor Anne Pereira, Ph.D. Pereira had co-founded Biolytx Pharmaceuticals with Hagstrom based on her groundbreaking work in developing peptides that kill antibiotic resistant bacteria.”
December 16, 2015 – Excerpt from OCRID: University of Oklahoma Health Sciences Center Professor Heloise Anne Pereira has been named a 2016 National Academy of Inventors Fellow, a high professional distinction awarded to academic inventors who have demonstrated a prolific spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development, and the welfare of society.
November 7, 2015 – Excerpt from NewsOK: A $500,000 investment from the i2E Inc.-managed Oklahoma Seed Capital Fund recently led a $1.1 million financing round in Oklahoma City-based Biolytx Pharmaceuticals Corp. Biolytx is developing a drug designed to promote wound healing and kill antibiotic resistant bacteria. This latest financing also included $200,000 from i2E-managed SeedStep Angels group, $250,000 from an Oklahoma venture capital fund and $150,000 in investment by Biolytx management.
March 25, 2015 – Excerpt from: Oklahoma JustGoodNews.Biz OKLAHOMA CITY — In 2004, i2E launched a “Meet the Scientist” speaker series in which Oklahoma researchers presented their findings to a local audience that was eager to hear about the potential of scientific discoveries. PHOTO: Dr. Anne Pereira, Dean of OU Health Sciences Center Graduate College…
December 8, 2014 – Excerpt from i2e: Just a few years ago, we lived in a world that wasn’t connected by wireless networks and instantaneous communication. So you might have felt a bit isolated if you were raised in, say, Australia. That was definitely the perception of Anne Pereira in the early 1980s as she…
University of Oklahoma Health Sciences Center Professor Heloise Anne Pereira has been named a 2016 National Academy of Inventors Fellow, a high professional distinction awarded to academic inventors who have demonstrated a prolific spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development, and the welfare of society.